Viatris has marked another milestone in its ongoing transformation by completing the previously-announced divestment of its active pharmaceutical ingredient business to Matrix Pharma Private Limited in India.
Viatris has completed another stage in the ongoing transformation of its business by closing the divestment of its active pharmaceutical ingredient business to India’s Matrix Pharma Private Limited.
Having in late 2022 earmarked the API business as a “non-core” asset that would be put up for sale –...
Create an account to read this article
Already a subscriber?
Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?
Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.
Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.
This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.
In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.
Neuraxpharm has launched its Australian affiliate as part of its continued international expansion beyond Europe. The company will introduce CNS treatments including its acquired Nuvigil, Provigil, and the recently TGA-approved Briumvi for multiple sclerosis.
